1851 Harbor Bay Parkway
680 articles with Exelixis, Inc.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
4/27/2020Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close.
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma
Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib
BMS and Exelixis Eye Potential Approval of RCC Combination Drug Following Positive Phase III Results
4/20/2020This morning, the two companies announced the positive topline results from the pivotal Phase III CheckMate -9ER study in previously untreated patients with renal cell carcinoma.
Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in a fireside chat as part of the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 11:20 AM EDT / 8:20 AM PDT.
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX ® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX ® (cabozantinib) in Japan, received approval from the
Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.
Exelixis, Inc. announced that members of Exelixis’ management team will provide a corporate overview at the following investor conferences in March
Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Exelixis, Inc. reported financial results for the fourth quarter and full year 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer
Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020
2/17/2020It was a very busy week for clinical trial news. Here’s a look.
Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 25, 2020 after the markets close.
In 2014, Exelixis’ Cabometyx (cabozantinib) failed to show survival benefit as a monotherapy in prostate cancer.
Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging results from the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors.
Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will be presenting at the following investor conferences in February
Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma
Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1/2 clinical trial results from the combination of cabozantinib (CABOMETYX®) and nivolumab (Opdivo®) with or without ipilimumab (Yervoy®) in advanced hepatocellular carcinoma (HCC)
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.